45
Participants
Start Date
March 7, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
May 31, 2026
Nabilone
Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
Placebo
The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
RECRUITING
University of British Columbia, St Paul's Hospital, Vancouver
NOT_YET_RECRUITING
Brain and Mind Institute, University of Western Ontario, London
RECRUITING
Sunnybrook Health Sciences Centre, Toronto
ACTIVE_NOT_RECRUITING
Baycrest Hospital, University of Toronto, Toronto
RECRUITING
Western Hospital - University of Toronto, Toronto
RECRUITING
CHU de Québec, Université Laval, Laval
RECRUITING
The Douglas Research Centre, Montreal
Alzheimer's Drug Discovery Foundation
OTHER
Simon Ducharme, MD
OTHER